KR970705381A - 흡수성 첨가제를 함유하는 에스트라디올 트랜스더멀 치료 시스템 - Google Patents
흡수성 첨가제를 함유하는 에스트라디올 트랜스더멀 치료 시스템Info
- Publication number
- KR970705381A KR970705381A KR1019970701108A KR19970701108A KR970705381A KR 970705381 A KR970705381 A KR 970705381A KR 1019970701108 A KR1019970701108 A KR 1019970701108A KR 19970701108 A KR19970701108 A KR 19970701108A KR 970705381 A KR970705381 A KR 970705381A
- Authority
- KR
- South Korea
- Prior art keywords
- matrix
- transdermal therapeutic
- therapeutic system
- estradiol
- glycerol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 활성물질 에스트라디올을 함유하고 활성물질 및 수분에 대해 불침투성을 지닌 백킹층으로 된 층상 구조를 가지며, 활성물질함유 매트릭스, 필요한 경우에 매트릭스를 감싸는 제거가능한 보호층으로 구성되는 트랜스더멀 치료 시스템에 있어서, 상기 매트릭스는 물 최대 흡수량이 1중량%이거나 실질적으로 물을 함유하지 않는 글리세롤을 포함하는 것을 특징으로 하는 트랜스더멀 치료 시스템에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 활성물질 에스트라디올을 함유하고 활성물질 및 수분에 대해 불침투성을 지닌 백킹층으로 된 층상 구조를 가지며, 활성물질함유 매트릭스, 필요한 경우에 매트릭스를 감싸는 제거 가능한 보호층으로 구성되는 트랜스더멀 치료 시스템에 있어서, 상기 매트릭스는 물 최대 흡수량이 1중량%이거나 실질적으로 물을 함유하지 않는 글리세롤을 포함하는 것을 특징으로 하는 트랜스더멀 치료 시스템
- 제1항에 있어서, 상기 매트릭스는 다수의 층으로 이루어지고, 이들 중 하나 이상의 층은 물 최대 흡수량이 1중량%이거나 실질적으로 물을 함유하지 않는 글리세롤을 포함하는 것을 특징으로 하는 트랜스더멀 치료 시스템.
- 제1항 또는 제2항에 있어서, 전체 매트릭스 물질 중의 무수 글리세롤의 비율은 1∼50중량%, 바람직하게는 10∼35중량%인 것을 특징으로 하는 트랜스더멀 치료 시스템.
- 제1항 또는 제3항 중 어느 한 항에 있어서, 매트릭스에 함유된 에스트라디올은 무수 결정체의 분산액으로서 존재하는 것을 특징으로 하는 트랜스더멀 치료 시스템.
- 제1항 또는 제4항 중 어느 한 항에 있어서, 매트릭스의 기제 또는 이들 층 중 한 층은 아크릴산 에스테르 공중합체인 것을 특징으로 하는 트랜스더멀 치료 시스템.
- 제5항에 있어서, 아크릴산 에스테르 공중합체는 에스트라디올 결정체의 용해도가 0.4∼3.0%인 것을 특징으로 하는 트랜스더멀 치료 시스템.
- a) 에스트라디올 반수화물과, 용액, 분산액 또는 매트릭스 기제의 용융물 중의 수결합 글리세롤의 현탁액을 제조하는 단계, b) 캐리어 포일을 현탁액으로 피복하는 단계, 및 c) 피복층을 50∼175℃으로 가열하여 건조시켜 에스트라디올 반수화물을 무수 에스트라디올로 변환시키는 단계로 구성되는 것을 특징으로 하는 제1항 내지 제6항 중 어느 한 항의 트랜스더멀 치료 시스템의 제조방법.
- 제7항에 있어서, 트랜스더멀 치료 시스템은 기밀하게 밀폐되고 건조제가 첨가된 패키지 수단에 팩킹되는 것을 특징으로 하는 트랜스더멀 치료 시스템의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4429667A DE4429667C2 (de) | 1994-08-20 | 1994-08-20 | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
DEP4429667.3 | 1994-08-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970705381A true KR970705381A (ko) | 1997-10-09 |
KR100401136B1 KR100401136B1 (ko) | 2004-03-31 |
Family
ID=6526231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970701108A KR100401136B1 (ko) | 1994-08-20 | 1995-08-12 | 흡수성첨가제를함유하는에스트라디올트랜스더멀치료시스템 |
Country Status (22)
Country | Link |
---|---|
US (1) | US5902602A (ko) |
EP (1) | EP0776199B1 (ko) |
JP (1) | JP3825799B2 (ko) |
KR (1) | KR100401136B1 (ko) |
CN (1) | CN1078461C (ko) |
AT (1) | ATE185067T1 (ko) |
AU (1) | AU695970B2 (ko) |
CZ (1) | CZ289397B6 (ko) |
DE (2) | DE4429667C2 (ko) |
DK (1) | DK0776199T3 (ko) |
ES (1) | ES2139932T3 (ko) |
FI (1) | FI118720B (ko) |
GR (1) | GR3032218T3 (ko) |
HU (1) | HU226959B1 (ko) |
IL (1) | IL114949A (ko) |
MX (1) | MX9701302A (ko) |
NO (1) | NO313984B1 (ko) |
NZ (1) | NZ291813A (ko) |
PL (1) | PL180965B1 (ko) |
SK (1) | SK281626B6 (ko) |
WO (1) | WO1996005814A1 (ko) |
ZA (1) | ZA956925B (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698217A (en) * | 1995-05-31 | 1997-12-16 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery device containing a desiccant |
DE19600347A1 (de) * | 1996-01-08 | 1997-07-10 | Lohmann Therapie Syst Lts | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
DE19713141A1 (de) * | 1996-03-29 | 1997-10-30 | Labtec Gmbh | Transdermales System mit Melatonin |
DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
CN117545474A (zh) | 2021-11-08 | 2024-02-09 | 李维庸 | 一种用于向患者递送药物的透皮给药*** |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE12731T1 (de) * | 1979-01-11 | 1985-05-15 | Key Pharma | Polymere diffusionsmatrix und verfahren zu deren herstellung. |
US4438139A (en) * | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
CA1163559A (en) * | 1980-07-09 | 1984-03-13 | Alec D. Keith | Polymeric diffusion matrix for administration of drugs |
DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
ZA853488B (en) * | 1984-05-10 | 1986-12-30 | American Home Prod | Transdermal dosage form |
US4810499A (en) * | 1984-10-01 | 1989-03-07 | Biotek, Inc. | Transdermal drug delivery system and method |
US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4764379A (en) * | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
US4863738A (en) * | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
DD279818A1 (de) * | 1989-02-06 | 1990-06-20 | Jenapharm Veb | Verfahren zur herstellung eines medizinischen pflasters |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
AR246186A1 (es) * | 1989-11-17 | 1994-07-29 | Beta Pharm Co | Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica. |
DE4210165A1 (de) * | 1991-07-30 | 1993-02-04 | Schering Ag | Transdermale therapeutische systeme |
US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
DE4210711A1 (de) * | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
ATE184473T1 (de) * | 1992-06-11 | 1999-10-15 | Theratech Inc | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung |
CA2161004C (en) * | 1993-04-20 | 2004-10-26 | Wilfried Fischer | Active ingredient patch |
-
1994
- 1994-08-20 DE DE4429667A patent/DE4429667C2/de not_active Expired - Fee Related
-
1995
- 1995-08-12 KR KR1019970701108A patent/KR100401136B1/ko not_active IP Right Cessation
- 1995-08-12 AT AT95929856T patent/ATE185067T1/de active
- 1995-08-12 SK SK220-97A patent/SK281626B6/sk not_active IP Right Cessation
- 1995-08-12 EP EP95929856A patent/EP0776199B1/de not_active Expired - Lifetime
- 1995-08-12 NZ NZ291813A patent/NZ291813A/en not_active IP Right Cessation
- 1995-08-12 WO PCT/EP1995/003201 patent/WO1996005814A1/de active IP Right Grant
- 1995-08-12 AU AU33449/95A patent/AU695970B2/en not_active Ceased
- 1995-08-12 JP JP50775496A patent/JP3825799B2/ja not_active Expired - Lifetime
- 1995-08-12 CN CN95194677A patent/CN1078461C/zh not_active Expired - Fee Related
- 1995-08-12 DE DE59506962T patent/DE59506962D1/de not_active Expired - Lifetime
- 1995-08-12 US US08/632,490 patent/US5902602A/en not_active Expired - Lifetime
- 1995-08-12 PL PL95319013A patent/PL180965B1/pl not_active IP Right Cessation
- 1995-08-12 ES ES95929856T patent/ES2139932T3/es not_active Expired - Lifetime
- 1995-08-12 HU HU9701729A patent/HU226959B1/hu not_active IP Right Cessation
- 1995-08-12 MX MX9701302A patent/MX9701302A/es unknown
- 1995-08-12 DK DK95929856T patent/DK0776199T3/da active
- 1995-08-12 CZ CZ1997509A patent/CZ289397B6/cs not_active IP Right Cessation
- 1995-08-15 IL IL11494995A patent/IL114949A/en not_active IP Right Cessation
- 1995-08-18 ZA ZA956925A patent/ZA956925B/xx unknown
-
1997
- 1997-01-28 NO NO19970360A patent/NO313984B1/no not_active IP Right Cessation
- 1997-02-19 FI FI970701A patent/FI118720B/fi not_active IP Right Cessation
-
1999
- 1999-12-22 GR GR990403305T patent/GR3032218T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5352456A (en) | Device for administering drug transdermally which provides an initial pulse of drug | |
US5230898A (en) | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof | |
ATE184473T1 (de) | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung | |
KR900015761A (ko) | 경피성 단일체 시스템 | |
NO900748L (no) | Terapeutisk system for retardert og kontrollert transdermal eller transslimhinne-administrering av aktive substanser (ii). | |
KR900002765A (ko) | 다중충 경고제 | |
JPH10505342A (ja) | 加水分解に対する保護を備えた経皮性治療システム | |
SI9300387B (sl) | Transdermalni terapevtski sistem z aktivno snovjo 17-beta-estradiolom (brezvodnim) | |
KR970705381A (ko) | 흡수성 첨가제를 함유하는 에스트라디올 트랜스더멀 치료 시스템 | |
ES2058627T3 (es) | Sistema terapeutico para la administracion retardada y dirigida a traves de la piel o de las mucosas de sustancias activas. | |
KR970705380A (ko) | 친수성 첨가제를 함유하는 에스트라디올 함유 트랜스더멀 치료 시스템 | |
NO983098D0 (no) | Hudheftende farmas°ytisk preparat, spesielt transdermalt terapeutisk system for frigivelse av 17-<beta>-estradiol til den menneskelige organisme | |
JPH0333687B2 (ko) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110920 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |